Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization

Journal of Immunology

Volumn 191, Issue 8, 2013, Pages 4130-4140

  Williams, Emily L ^a   Tutt, Alison L ^a   Beers, Stephen A ^a   French, Ruth R ^a   Chan, Claude H T ^a   Cox, Kerry L ^a   Roghanian, Ali ^a   Penfold, Christine A ^a   Butts, Cherié L ^b   Boross, Peter ^c   Verbeek, J Sjef ^c   Cragg, Mark S ^a   Glennie, Martin J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b BIOGEN   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CD20 ANTIBODY; FC RECEPTOR IIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY AT128 M2A; MONOCLONAL ANTIBODY AT130 2; MONOCLONAL ANTIBODY MC106A5; MONOCLONAL ANTIBODY MC39 16; RITUXIMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL PHAGOCYTOSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HOST CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CELLS, CULTURED; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, KNOCKOUT; MULTIPLE MYELOMA; RECEPTORS, IGG;

EID: 84885453544     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1301430     Document Type: Article

References (74)

1. Glennie, M. J., and J. G. van de Winkel. 2003. Renaissance of cancer therapeutic antibodies. Drug Discov. Today 8: 503-510.
2. Glennie, M. J., and P. W. Johnson. 2000. Clinical trials of antibody therapy. Immunol. Today 21: 403-410.
3. Glennie, M. J., R. R. French, M. S. Cragg, and R. P. Taylor. 2007. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol. Immunol. 44: 3823-3837.
4. Nimmerjahn, F., and J. V. Ravetch. 2008. Fcg receptors as regulators of immune responses. Nat. Rev. Immunol. 8: 34-47.
5. Ravetch, J. V., and S. Bolland. 2001. IgG Fc receptors. Annu. Rev. Immunol. 19: 275-290.
6. Xiang, Z., A. J. Cutler, R. J. Brownlie, K. Fairfax, K. E. Lawlor, E. Severinson, E. U. Walker, R. A. Manz, D. M. Tarlinton, and K. G. Smith. 2007. FcgRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 8: 419-429.
7. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6: 443-446.
8. Hamaguchi, Y., Y. Xiu, K. Komura, F. Nimmerjahn, and T. F. Tedder. 2006. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203: 743-753.
9. Kaneko, Y., F. Nimmerjahn, and J. V. Ravetch. 2006. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.
10. Nimmerjahn, F., and J. V. Ravetch. 2007. Antibodies, Fc receptors and cancer. Curr. Opin. Immunol. 19: 239-245.
11. Kaminski, M. S., K. Kitamura, D. G. Maloney, M. J. Campbell, and R. Levy. 1986. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J. Immunol. 136: 1123-1130.
12. Kipps, T. J., P. Parham, J. Punt, and L. A. Herzenberg. 1985. Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J. Exp. Med. 161: 1-17.
13. Tedder, T. F., A. Baras, and Y. Xiu. 2006. Fcg receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity. Springer Semin. Immunopathol. 28: 351-364.
14. Uchida, J., Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669.
15. Bevaart, L., J. Goldstein, L. Vitale, C. Russoniello, J. Treml, J. Zhang, R. F. Graziano, J. H. Leusen, J. G. van de Winkel, and T. Keler. 2006. Direct targeting of genetically modified tumour cells to FcgRI triggers potent tumour cytotoxicity. Br. J. Haematol. 132: 317-325.
16. Nimmerjahn, F., and J. V. Ravetch. 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310: 1510-1512.
17. Fossati-Jimack, L., A. Ioan-Facsinay, L. Reininger, Y. Chicheportiche, N. Watanabe, T. Saito, F. M. Hofhuis, J. E. Gessner, C. Schiller, R. E. Schmidt, et al. 2000. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-Affinity Fcg receptor III. J. Exp. Med. 191: 1293-1302.
18. Shields, R. L., A. K. Namenuk, K. Hong, Y. G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, et al. 2001. High resolution mapping of the binding site on human IgG1 for FcgRI, FcgRII, FcgRIII, and FcRn and design of IgG1 variants with improved binding to the FcgR. J. Biol. Chem. 276: 6591-6604.
19. Wu, J., J. C. Edberg, P. B. Redecha, V. Bansal, P. M. Guyre, K. Coleman, J. E. Salmon, and R. P. Kimberly. 1997. A novel polymorphism of FcgRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 100: 1059-1070.
20. Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 99: 754-758.
21. Weng, W. K., and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21: 3940-3947.
22. Tsuchiya, N., Z. Honda, and K. Tokunaga. 2006. Role of B cell inhibitory receptor polymorphisms in systemic lupus erythematosus: a negative times a negative makes a positive. J. Hum. Genet. 51: 741-750.
23. Olferiev, M., E. Masuda, S. Tanaka, M. C. Blank, and L. Pricop. 2007. The role of activating protein 1 in the transcriptional regulation of the human FCGR2B promoter mediated by the-343 G → C polymorphism associated with systemic lupus erythematosus. J. Biol. Chem. 282: 1738-1746.
24. McGaha, T. L., M. C. Karlsson, and J. V. Ravetch. 2008. FcgRIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl-MpJ mice. J. Immunol. 180: 5670-5679.
25. Kono, H., C. Kyogoku, T. Suzuki, N. Tsuchiya, H. Honda, K. Yamamoto, K. Tokunaga, and Z. Honda. 2005. FcgRIIB Ile232Thr transmembrane polymorphism associated with human systemic lupus erythematosus decreases affinity to lipid rafts and attenuates inhibitory effects on B cell receptor signaling. Hum. Mol. Genet. 14: 2881-2892.
26. Fukuyama, H., F. Nimmerjahn, and J. V. Ravetch. 2005. The inhibitory Fcg receptor modulates autoimmunity by limiting the accumulation of immunoglobulin G+ anti-DNA plasma cells. Nat. Immunol. 6: 99-106.
27. Floto, R. A., M. R. Clatworthy, K. R. Heilbronn, D. R. Rosner, P. A. MacAry, A. Rankin, P. J. Lehner, W. H. Ouwehand, J. M. Allen, N. A. Watkins, and K. G. Smith. 2005. Loss of function of a lupus-Associated FcgRIIb polymorphism through exclusion from lipid rafts. Nat. Med. 11: 1056-1058.
28. Yuasa, T., S. Kubo, T. Yoshino, A. Ujike, K. Matsumura, M. Ono, J. V. Ravetch, and T. Takai. 1999. Deletion of Fcg receptor IIB renders H-2b mice susceptible to collagen-induced arthritis. J. Exp. Med. 189: 187-194.
29. Rankin, C. T., M. C. Veri, S. Gorlatov, N. Tuaillon, S. Burke, L. Huang, H. D. Inzunza, H. Li, S. Thomas, S. Johnson, et al. 2006. CD32B, the human inhibitory Fc-g receptor IIB, as a target for monoclonal antibody therapy of Bcell lymphoma. Blood 108: 2384-2391.
30. Stavenhagen, J. B., S. Gorlatov, N. Tuaillon, C. T. Rankin, H. Li, S. Burke, L. Huang, S. Vijh, S. Johnson, E. Bonvini, and S. Koenig. 2007. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-Affinity activating Fcg receptors. Cancer Res. 67: 8882-8890.
31. Veri, M. C., S. Gorlatov, H. Li, S. Burke, S. Johnson, J. Stavenhagen, K. E. Stein, E. Bonvini, and S. Koenig. 2007. Monoclonal antibodies capable of discriminating the human inhibitory Fcg-receptor IIB (CD32B) from the activating Fcgreceptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 121: 392-404.
32. Williams, E. L., A. L. Tutt, R. R. French, H. T. Chan, B. Lau, C. A. Penfold, C. I. Mockridge, A. Roghanian, K. L. Cox, J. S. Verbeek, et al. 2012. Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcgRIIB (CD32B). Eur. J. Immunol. 42: 2109-2120.
33. Beers, S. A., C. H. Chan, S. James, R. R. French, K. E. Attfield, C. M. Brennan, A. Ahuja, M. J. Shlomchik, M. S. Cragg, and M. J. Glennie. 2008. Type II (tositumomab) anti-CD20monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 112: 4170-4177.
34. Boross, P., V. L. Arandhara, J. Martin-Ramirez, M. L. Santiago-Raber, F. Carlucci, R. Flierman, J. van der Kaa, C. Breukel, J. W. Claassens, M. Camps, et al. 2011. The inhibiting Fc receptor for IgG, FcgRIIB, is a modifier of autoimmune susceptibility. J. Immunol. 187: 1304-1313.
35. Sharp, P. E., J. Martin-Ramirez, P. Boross, S. M. Mangsbo, J. Reynolds, J. Moss, C. D. Pusey, H. T. Cook, R. M. Tarzi, and J. S. Verbeek. 2012. Increased incidence of anti-GBM disease in Fcg receptor 2b deficient mice, but not mice with conditional deletion of Fcgr2b on either B cells or myeloid cells alone. Mol. Immunol. 50: 49-56.
36. van Montfoort, N., P. A. 't Hoen, S. M. Mangsbo, M. G. Camps, P. Boross, C. J. Melief, F. Ossendorp, and J. S. Verbeek. 2012. Fcg receptor IIb strongly regulates Fcg receptor-facilitated T cell activation by dendritic cells. J. Immunol. 189: 92-101.
37. Slavin, S., and S. Strober. 1978. Spontaneous murine B-cell leukaemia. Nature 272: 624-626.
38. Cobb, L. M.,M. J. Glennie, H. M. McBride, G. Breckon, and T. C. Richardson. 1986. Characterisation of a new murine B cell lymphoma. Br. J. Cancer 54: 807-818.
39. Illidge, T., J. Honeychurch, W. Howatt, F. Ross, B. Wilkins, and M. Cragg. 2000. A new in vivo and in vitro B cell lymphoma model, p-BCL1. Cancer Biother. Radiopharm. 15: 571-580.
40. Glennie, M. J., H. M. McBride, A. T. Worth, and G. T. Stevenson. 1987. Preparation and performance of bispecific F(ab9 gamma)2 antibody containing thioether-linked Fab9 gamma fragments. J. Immunol. 139: 2367-2375.
41. Greenman, J., A. L. Tutt, A. J. George, K. A. Pulford, G. T. Stevenson, and M. J. Glennie. 1991. Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab9)2 derivative for recruitment of cytotoxic effectors. Mol. Immunol. 28: 1243-1254.
42. Looney, R. J., G. N. Abraham, and C. L. Anderson. 1986. Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J. Immunol. 136: 1641-1647.
43. Pulford, K., E. Ralfkiaer, S. M. MacDonald, W. N. Erber, B. Falini, K. C. Gatter, and D. Y. Mason. 1986. A new monoclonal antibody (KB61) recognizing a novel antigen which is selectively expressed on a subpopulation of human B lymphocytes. Immunology 57: 71-76.
44. Brezinsky, S. C., G. G. Chiang, A. Szilvasi, S. Mohan, R. I. Shapiro, A. MacLean, W. Sisk, and G. Thill. 2003. A simple method for enriching populations of transfected CHO cells for cells of higher specific productivity. J. Immunol. Methods 277: 141-155.
45. George, A. J., H. M. McBride, M. J. Glennie, L. J. Smith, and F. K. Stevenson. 1991. Monoclonal antibodies raised against the idiotype of the murine B cell lymphoma, BCL1 act primarily with heavy chain determinants. Hybridoma 10: 219-227.
46. Tutt, A. L., R. R. French, T. M. Illidge, J. Honeychurch, H. M. McBride, C. A. Penfold, D. T. Fearon, R. M. Parkhouse, G. G. Klaus, and M. J. Glennie. 1998. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J. Immunol. 161: 3176-3185.
47. Beers, S. A., R. R. French, H. T. Chan, S. H. Lim, T. C. Jarrett, R. M. Vidal, S. S. Wijayaweera, S. V. Dixon, H. Kim, K. L. Cox, et al. 2010. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 115: 5191-5201.
48. Lim, S. H., A. T. Vaughan, M. Ashton-Key, E. L. Williams, S. V. Dixon, H. T. Chan, S. A. Beers, R. R. French, K. L. Cox, A. J. Davies, et al. 2011. Fcg receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118: 2530-2540.
49. Beum, P. V., A. D. Kennedy, M. E. Williams, M. A. Lindorfer, and R. P. Taylor. 2006. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J. Immunol. 176: 2600-2609.
50. Boross, P., J. H. Jansen, A. Pastula, C. E. van der Poel, and J. H. Leusen. 2012. Both activating and inhibitory Fcg receptors mediate rituximab-induced trogocytosis of CD20 in mice. Immunol. Lett. 143: 44-52.
51. Joshi, T., L. P. Ganesan, X. Cao, and S. Tridandapani. 2006. Molecular analysis of expression and function of hFcgRIIbl and b2 isoforms in myeloid cells. Mol. Immunol. 43: 839-850.
52. Cassel, D. L., M. A. Keller, S. Surrey, E. Schwartz, A. D. Schreiber, E. F. Rappaport, and S. E. McKenzie. 1993. Differential expression of FcgRIIA, FcgRIIB and FcgRIIC in hematopoietic cells: analysis of transcripts. Mol. Immunol. 30: 451-460.
53. Budde, P., N. Bewarder, V. Weinrich, O. Schulzeck, and J. Frey. 1994. Tyrosinecontaining sequence motifs of the human immunoglobulin G receptors FcRIIb1 and FcRIIb2 essential for endocytosis and regulation of calcium flux in B cells. J. Biol. Chem. 269: 30636-30644.
54. Van Den Herik-Oudijk, I. E., N. A. Westerdaal, N. V. Henriquez, P. J. Capel, and J. G. Van De Winkel. 1994. Functional analysis of human FcgRII (CD32) isoforms expressed in B lymphocytes. J. Immunol. 152: 574-585.
55. Elliott, T. J., M. J. Glennie, H. M. McBride, and G. T. Stevenson. 1987. Analysis of the interaction of antibodies with immunoglobulin idiotypes on neoplastic B lymphocytes: implications for immunotherapy. J. Immunol. 138: 981-988.
56. Lane, A. C., S. Foroozan, M. J. Glennie, P. Kowalski-Saunders, and G. T. Stevenson. 1991. Enhanced modulation of antibodies coating guinea pig leukemic cells in vitro and in vivo. The role of FcgR expressing cells. J. Immunol. 146: 2461-2468.
57. Weiner, L. M., R. Surana, and S. Wang. 2010. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10: 317-327.
58. Nelson, A. L., E. Dhimolea, and J. M. Reichert. 2010. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9: 767-774.
59. Lee, C. S., M. S. Cragg, M. J. Glennie, and P. W. Johnson. 2013. Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br. J. Clin. Pharmacol. 76: 233-247.
60. Takeda, K., N. Yamaguchi, H. Akiba, Y. Kojima, Y. Hayakawa, J. E. Tanner, T. J. Sayers, N. Seki, K. Okumura, H. Yagita, and M. J. Smyth. 2004. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199: 437-448.
61. White, A. L., H. T. Chan, A. Roghanian, R. R. French, C. I. Mockridge, A. L. Tutt, S. V. Dixon, D. Ajona, J. S. Verbeek, A. Al-Shamkhani, et al. 2011. Interaction with FcgRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187: 1754-1763.
62. Li, F., and J. V. Ravetch. 2011. Inhibitory Fcg receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333: 1030-1034.
63. Li, J., D. E. van der Wal, L. Zhu, B. Vadasz, E. K. Simpson, C. Li, M. L. Webster, G. Zhu, S. Lang, P. Chen, et al. 2013. Fc-independent phagocytosis: implications for IVIG and other therapies in immune-mediated thrombocytopenia. Cardiovasc. Hematol. Disord. Drug Targets 13: 50-58.
64. Sedmak, D. D., D. H. Davis, U. Singh, J. G. van de Winkel, and C. L. Anderson. 1991. Expression of IgG Fc receptor antigens in placenta and on endothelial cells in humans. An immunohistochemical study. Am. J. Pathol. 138: 175-181.
65. Gröger, M., G. Sarmay, E. Fiebiger, K. Wolff, and P. Petzelbauer. 1996. Dermal microvascular endothelial cells express CD32 receptors in vivo and in vitro. J. Immunol. 156: 1549-1556.
66. Lyden, T. W., J. M. Robinson, S. Tridandapani, J. L. Teillaud, S. A. Garber, J. M. Osborne, J. Frey, P. Budde, and C. L. Anderson. 2001. The Fc receptor for IgG expressed in the villus endothelium of human placenta is FcgRIIb2. J. Immunol. 166: 3882-3889.
67. Unkeless, J. C., and J. Jin. 1997. Inhibitory receptors, ITIM sequences and phosphatases. Curr. Opin. Immunol. 9: 338-343.
68. D'Ambrosio, D., D. C. Fong, and J. C. Cambier. 1996. The SHIP phosphatase becomes associated with FcgRIIB1 and is tyrosine phosphorylated during "negative" signaling. Immunol. Lett. 54: 77-82.
69. Long, E. O. 1999. Regulation of immune responses through inhibitory receptors. Annu. Rev. Immunol. 17: 875-904.
70. Cox, D., B. M. Dale, M. Kashiwada, C. D. Helgason, and S. Greenberg. 2001. A regulatory role for Src homology 2 domain-containing inositol 59-phosphatase (SHIP) in phagocytosis mediated by Fcg receptors and complement receptor 3 (aMb2; CD11b/CD18). J. Exp. Med. 193: 61-71.
71. Kant, A. M., P. De, X. Peng, T. Yi, D. J. Rawlings, J. S. Kim, and D. L. Durden. 2002. SHP-1 regulates Fcg receptor-mediated phagocytosis and the activation of RAC. Blood 100: 1852-1859.
72. Ganesan, L. P., J. Kim, Y. Wu, S. Mohanty, G. S. Phillips, D. J. Birmingham, J. M. Robinson, and C. L. Anderson. 2012. FcgRIIb on liver sinusoidal endothelium clears small immune complexes. J. Immunol. 189: 4981-4988.
73. Miettinen, H. M., J. K. Rose, and I. Mellman. 1989. Fc receptor isoforms exhibit distinct abilities for coated pit localization as a result of cytoplasmic domain heterogeneity. Cell 58: 317-327.
74. Flores, M., D. D. Desai, M. Downie, B. Liang, M. P. Reilly, S. E. McKenzie, and R. Clynes. 2009. Dominant expression of the inhibitory FcgRIIB prevents antigen presentation by murine plasmacytoid dendritic cells. J. Immunol. 183: 7129-7139.